The pharmaceutical industry is one of the most developed business sectors in Switzerland. A significant part of the largest Swiss companies are companies operating in the pharmaceutical industry, being global leaders in the production of medicines, medical equipment, and related products. These companies are making groundbreaking discoveries every year, helping to cure diseases and improving the quality of life for millions of people. These advancements are being made in laboratories that use the most sophisticated equipment, perhaps from somewhere like https://www.sciquip.co.uk/products/shaking-incubators.html, so they can remain at the cutting edge of medical technology.
Novartis operates globally and maintains close ties with its customers, focusing on patented innovative drugs, generics drugs and ophthalmic devices. The global portfolio of patented and commercialized medicines comprises over 50 essential products, many of which rank first in their therapeutic areas.
Novartis Institute for Biomedical Research (NIBR), which counts over 6,000 researchers and physicians worldwide, represents the force behind Novartis’ innovative products. NIBR focuses on the discovery of new drugs that can change the practice of medicine. With a market capitalization of 270 billion USD, it’s easy to see why Novartis can be considered as one of the largest Swiss companies, not only in the pharmaceutical sector. Contact davidboehrerlaw.com if ever in doubt.
Headquartered in Basel, Switzerland, Roche is one of the world’s leading pharmaceutical and diagnostic research-based research teams with the synergy offered by its two divisions: the Pharmaceutical Division and the Diagnostic Division. Roche is the world’s largest biotech company offering clinically differentiated drugs in the field of oncology, immunology, infectious diseases, ophthalmology, and central nervous system disorders. Roche is also a world leader in in vitro diagnosis and histological diagnosis of cancer, as well as a pioneer in diabetes management.
Founded in 1896, Roche has contributed, for over a century, to improving people’s health at a global level. 28 drugs developed by Roche, including antibiotics, malaria drugs and chemotherapy, are on the List of Essential Medicines developed by the World Health Organization.
In 2014, Roche had over 88,500 employees globally, invested 8.9 billion CHF in research and development and reported sales of 47.5 billion CHF, not to mention a market capitalization of 240 billion USD, being on top of the list of the largest Swiss companies.
Basilea Pharmaceutica AG
Basilea Pharmaceutica is a multinational company specialized in biopharmaceutical activities, with the headquarters in Basel, Switzerland. It was formed in 2000, as a separate legal entity from the Hoffmann-La Roche drug giant. The company develops, distributes, researches, markets and promotes drugs used for the treatment of skin disease, bacterial and fungal infections. Although it doesn’t have the century-old tradition of other companies included on this list, Basilea Pharmaceutica managed to become one of the largest Swiss companies in the pharmaceutical sector due to its innovative products and excellent results obtained through research activities.
Cilag is a Swiss pharmaceutical company that is a subsidiary of the American giant Johnson & Johnson. The company develops active treatments for patients in five major therapeutic areas in the medical field: cardiovascular and metabolic diseases, immunological diseases, infectious diseases and vaccines, neuroscience and oncology. Through extensive medical research, the pharmaceutical solutions proposed by Cilag can mitigate, cure or treat some of the most severe illnesses and conditions. Because of its presence on many international markets, Cilag can be considered one of the largest Swiss companies.
Headquartered in Switzerland, Ferring Pharmaceuticals is a specialized, research-oriented biopharmaceutical group, active on international markets. The company identifies, develops and markets innovative products in the fields of reproductive health, urology, gastroenterology and endocrinology.
In recent years, Ferring has expanded beyond its traditional European base, and currently has more than 4,000 employees and representations in 50 countries. Ferring’s international operations are overseen in Saint-Prex, Switzerland, and development activities are coordinated from Copenhagen, Denmark, and Parsippany, USA. Ferring owns production facilities in several countries in Europe, Israel, China, Mexico and Argentina, being one of the largest Swiss companies that activates in the pharmaceutical sector.